Christian Rommel
Directeur Technique/Scientifique/R&D chez BAYER AG
Fortune : - $ au 30/06/2024
Profil
Christian Rommel's current jobs include being a Director at Asklepios BioPharmaceutical, Inc., a Director at Vividion Therapeutics, Inc., a Director at CRISPR Therapeutics AG, and the Head of Research & Development at Bayer AG.
Dr. Rommel's former jobs include being a Senior Scientist at Regeneron Pharmaceuticals, Inc., the Chief Scientific Officer at Intellikine LLC from 2007 to 2012, the Head of Target Research at Merck Serono Ltd., the VP of External Research & Development at Amgen, Inc., and the SVP and Head of Oncology Research & Early Development at F.
Hoffmann-La Roche Ltd.
from 2018 to 2021.
Dr. Rommel obtained a doctorate degree from the Max-Planck-Institute for Molecular Genetics and an undergraduate degree from the University of Greifswald.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CRISPR THERAPEUTICS AG
-.--% | 30/05/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Christian Rommel
| Sociétés | Poste | Début |
|---|---|---|
| BAYER AG | Directeur Technique/Scientifique/R&D | 01/02/2021 |
| CRISPR THERAPEUTICS AG | Directeur/Membre du Conseil | 13/03/2024 |
Asklepios BioPharmaceutical, Inc.
 Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Christian Rommel
| Sociétés | Poste | Fin |
|---|---|---|
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/02/2021 |
Intellikine LLC
 Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Directeur Technique/Scientifique/R&D | 01/12/2012 |
| AMGEN INC. | Directeur Technique/Scientifique/R&D | - |
Merck Serono Ltd.
 Merck Serono Ltd. Miscellaneous Commercial ServicesCommercial Services Merck Serono Ltd. provides research and development services and manufactures medicinal drugs. The company is headquartered in Middlesex, the United Kingdom. | Corporate Officer/Principal | - |
| REGENERON PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Christian Rommel
| Max-Planck-Institute for Molecular Genetics | Doctorate Degree |
| University of Greifswald | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| BAYER AG | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
Merck Serono Ltd.
Merck Serono Ltd. Miscellaneous Commercial ServicesCommercial Services Merck Serono Ltd. provides research and development services and manufactures medicinal drugs. The company is headquartered in Middlesex, the United Kingdom. | Commercial Services |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Asklepios BioPharmaceutical, Inc.
Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. | Health Technology |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
